Research Article

Antileukemic Potential of Momordica charantia Seed Extracts on Human Myeloid Leukemic HL60 Cells

Ramani Soundararajan, Punit Prabha, Umesh Rai, and Aparna Dixit

1 Gene Regulation Laboratory, School of Biotechnology, Jawaharlal Nehru University, New Delhi 110 067, India
2 Department of Zoology, University of Delhi, New Delhi 110 007, India

Correspondence should be addressed to Aparna Dixit, adixit7@gmail.com

Received 7 January 2012; Revised 20 February 2012; Accepted 21 February 2012

Academic Editor: Raffaele Capasso

Copyright © 2012 Ramani Soundararajan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Momordica charantia (bitter gourd) has been used in the traditional system of medicine for the treatment of various diseases. Anticancer activity of M. charantia extracts has been demonstrated by numerous in vitro and in vivo studies. In the present study, we investigated the differentiation inducing potential of fractionated M. charantia seed extracts in human myeloid HL60 cells. We found that the HL60 cells treated with the fractionated seed extracts differentiated into granulocytic lineage as characterized by NBT staining, CD11b expression, and specific esterase activity. The differentiation inducing principle was found to be heat-stable, and organic in nature. The differentiation was accompanied by a downregulation of c-myc transcript, indicating the involvement of c-myc pathway, at least in part, in differentiation. Taken together these results indicate that fractionated extracts of M. charantia seeds possess differentiation inducing activity and therefore can be evaluated for their potential use in differentiation therapy for leukemia in combination with other inducers of differentiation.

1. Introduction

Acute myeloid leukemia (AML) is a complex disease, characterized by abnormal differentiation and unlimited cellular proliferation that develops due to the accumulation of genetic and epigenetic alterations. Current treatments including chemotherapeutic drugs, radiation, and stem cell transplantation are associated with incomplete remission and side effects [1]. Therefore, there is a need to discover novel anticancer drugs that are effective and have minimal side-effects associated with the treatment. In traditional system of medicine and folklores, plant-based formulations with potential antitumor properties have been described [2, 3]. Investigating dietary compounds with potential chemopreventive and anticancer activity has provided important leads for the development of clinically relevant anticancer drugs [3, 4] However, systematic scientific studies have been lacking to understand the mechanism(s) of their anticancer activity.

In the present study, we have focused our attention on a tropical plant, Momordica charantia L, belonging to Cucurbitaceae family that has been used in the traditional health care world over and the ethnobotanical use of this medicinal plant is well documented [5, 6]. M. charantia has been reported to possess a number of diverse medicinal properties such as antimicrobial, antidiabetic, antifertility and abortifacient activity [7–10]. Antiproliferative properties of fractionated M. charantia whole plant extracts were first reported by West et al. [11]. Subsequently, a number of growth inhibitors have been isolated from M. charantia seeds and its antiproliferative activity has been demonstrated in a variety of tumor cell lines [8, 12–15]. M. charantia fruit extract and its components have also been shown to be cytotoxic to leukemic lymphocytes and induce antitumor activity in vivo [8, 16, 17].

While antiproliferative and antitumor activity of M. charantia has been demonstrated, its differentiation inducing potential in leukemic cell lines has not been investigated. We have used human myeloid leukemic HL60 cells as an in vitro system to test the differentiation inducing potential of M. charantia and to elucidate the molecular mechanisms involved in the differentiation process. HL60 cells have been used for screening of compounds for their
antileukemic potential and to elucidate the molecular mechanisms involved in the differentiation process. Different compounds have been reported to induce HL60 cells towards granulocytic, macrophagic, and monocytic lineage [18–21]. In the present study, we report for the first time that the fractionated *M. charantia* seed extract induced differentiation of HL60 to granulocytes and thus has potential to be developed as a therapeutic supplement.

2. Material and Methods

2.1. Cells and Reagents. The human promyelocytic leukemia HL60 cells (ATCC#CCL240) were maintained in 1 × RPMI 1640 medium supplemented with fetal calf serum (FCS, 20%), penicillin (100 U/mL), and streptomycin (100 μg/mL) and 2 mM L-glutamine in a 5% CO₂ humidified atmosphere. The chemicals required for cell culture were procured from Biological Industries, Israel. Other chemicals were from standard commercial suppliers.

2.2. Extraction and Partial Purification of *M. charantia* Seed Extract. Seeds of *M. charantia* L. (Pusa Vishesh variety, developed, verified, and released by Indian Agriculture Research Institute (IARI), Pusa, New Delhi [22]) were obtained from IARI, Pusa, New Delhi. Decorticated seeds (100 g) were extracted in 75% ethanol containing 0.2 N HCl and 1 mM PMSF. The crude extract was centrifuged at 20,000 × g for 1 hr at 4°C. The supernatant was evaporated to 1/4 volume under reduced pressure followed by neutralization using NH₄OH. Differential fractionation of the extract (Mc-1, dry weight ~16.5 g) thus obtained using 0.05 M (NH₄)₂CO₃ followed by centrifugation at 20,000 × g for 45 min at 4°C resulted in the pellet (Mc-2, dry weight ~2.3 g) and supernatant (Mc-3, dry weight ~14.2 g) fractions. All the fractions were evaporated and resuspended in Milli-Q water prior to use. The fraction Mc-2 was further fractionated using acetone extraction (Mc-2Ac, dry weight ~400 mg). Protein was estimated using Lowry’s method [23].

2.3. Cell Viability and Cell Proliferation Assay. Cell viability of HL60 cells upon treatment with *M. charantia* fractions, namely, Mc-1, Mc-2, Mc-3, and Mc-2Ac was assayed using MTT essentially as described by Yedjou et al. [24]. HL60 cells were seeded in 96-well plate at an initial density of 10⁵ cells/mL. Different concentrations *M. charantia* test fractions (diluted in the medium) were added to the cells. The blank sample contained medium only. The cells were placed in humidified 5% CO₂ incubator at 37°C. After 72 h of incubation, the cells were centrifuged at 800 rpm for 5 min and the supernatant culture medium carefully aspirated. The cells were given 2 washes with PBS, followed by addition of 200 μL fresh medium containing MTT (0.5 mg/mL). The cells were further incubated at 37°C for 2 h, followed by centrifugation at 800 rpm for 5 min. The medium containing MTT was carefully removed followed by addition of 100 μL DMSO to each well. The plate was incubated at room temperature with shaking for 10 min to solubilize formazan crystals. The absorbance at 570 nm was measured in a microplate reader (Tecan, Switzerland). The absorbance produced is directly proportional to the number of viable cells. All assays were done in triplicates for each concentration and cell viability was estimated by using means ± SD values for each treatment. Cell viability was calculated using MTT absorbance of the control and treated cells: % survival = (mean value treated sample/mean value of untreated sample) × 100.

Effect of *M. charantia* fractions on cell proliferation rate was determined by viable cell count using a hemocytometer as described by Lee et al. [20]. Briefly, HL60 cells (10⁵ cells/mL) were plated in a 24-well plate and incubated with different fractions of *M. charantia* at a final concentration of 20 μg/mL for 5 days. Viable cell counts were determined on each day post treatment using trypan blue dye exclusion assay using a light microscope (Leica, Germany).

2.4. Differentiation of HL60 Cells. HL60 cells (2 × 10⁵/mL) were incubated with the test fractions at the indicated concentrations for different time intervals. Cell differentiation was assayed by NBT (Nitroblue tetrazolium) reduction, Wright-Giemsa staining, specific and nonspecific esterase activities, and by FACS analysis.

2.5. Nitroblue Tetrazolium (NBT) Reduction. NBT staining was used to assay for HL60 cell differentiation essentially as described earlier [25]. Approximately 200 cells in triplicates were scored under a light microscope (Leica, Germany) for each test sample. Extent of differentiation is expressed as number of % NBT positive cells. The data corresponding to the number of total NBT positive cells out of the total cells counted for different experiments are given in Table 1 in supplementary material available online at doi: 10.1155/2012/732404. The data were analyzed using one-way ANOVA and Tukey post hoc test to compare the difference between the treated and the untreated control. An alpha value of <0.05 was considered to be significant.

2.6. Wright-Giemsa Staining. Morphological changes in the HL60 cells induced by the test samples were evaluated using Wright-Giemsa staining as per the manufacturer’s instructions (Sigma-Aldrich, USA). Differential cell count was performed under a light microscope (Leica, Germany) from at least 3 independent glass slides for each experimental time point in triplicates.

2.7. Specific and Nonspecific Esterase Activity. Specific and nonspecific esterase activities in the HL60 cell lysates of the control and treated cells were estimated using cytochemical kits as per manufacturer’s instruction (Sigma 91-A and 91-C, Sigma-Aldrich, USA). The presence of granulation (redish and blackish granulation indicating the specific and nonspecific esterase, respectively) indicated the areas of enzyme activity, which was scored in a scale of 0 to +4, 0 indicating no staining, hence no enzyme activity and +4
indicating brilliant staining, and hence maximal enzyme activity.

2.8. Analysis for CD11b Expression. Control and treated HL60 cells (5 × 10^5 cells) washed with PBS containing 1% FCS and 0.01% sodium azide were incubated for 30 min in fetal calf serum at 4°C. Subsequently, FITC-conjugated anti-human CD11b antibody (1 μg/mL, eBiosciences, USA) was added to the cells and incubated at 25°C for 45 min followed by washing with PBS. The cells were then fixed in 1% paraformaldehyde and analyzed on Becton Dickinson Flow cytometer. Isotypic control (Rat IgG2b) was also used to check for nonspecific binding. The results were plotted using WinMdi software (Flow Core Facility, Scripps Research Institute; http://facs.scripps.edu/software.html).

2.9. Northern Blot Analysis of c-myc Transcript. HL60 cells (2 × 10^5 cells/mL) were treated with fractions Mc-2 and Mc-2Ac (20 μg/mL each). Total RNA from the control and treated cells was isolated on day 4 of the treatment using TRIzol reagent (Life Technologies, USA) as per the manufacturer’s instructions. Briefly, total RNA (10 μg each) isolated from the control and treated HL60 cells resolved on 1% formaldehyde agarose gel was transferred onto nitrocellulose membrane and subjected to Northern blotting using α-32P-dCTP-labeled c-myc gene specific probe [26] essentially as described earlier [27].

3. Results

3.1. Acid Ethanol Extractable Fractions of M. charantia Seeds Induce Differentiation of HL60 Cells. Analysis of differentiation in HL60 cells treated with fraction Mc-1 revealed that it was capable of inducing differentiation as established by an increase in number of NBT positive cells. Maximum differentiation (~30%) was observed at 10 μg/mL of Mc-1 (Figure 1(a)). However, treatment with higher concentrations of Mc-1 (20 μg/mL) resulted only in 22–25% differentiation. Further fractionation of Mc-1 into fractions Mc-2 and Mc-3 resulted in the enrichment of the differentiation-inducing principle(s) in fraction Mc-2. Approximately 50% cells stained positive with Mc-2 (10 μg/mL) with no further increase in differentiation at higher concentration (20 μg/mL). The fraction Mc-3 showed minimal differentiation (Figure 1(a)).

In order to assess if the observed increase in NBT positive cells is due to death of immature cells caused by the test fractions, cytotoxicity analysis was carried out with the fractions Mc-1, Mc-2, and Mc-3 of M. charantia. No effect on the cell viability was observed with any of the fractions up to 100 μg/mL (the maximum concentration tested; Figure 1(b)). These data indicate that the three fractions were noncytotoxic even at 5× concentrations than those used for differentiation studies (Figure 1(a)). Similar results were also obtained using Alamar blue reduction assay for cell survival. Percentage reduction of Alamar blue in HL60 cells treated with the three factions was comparable to the control cells confirming that the M. charantia fractions were noncytotoxic (data not shown).

3.2. Time Course of Induction of Differentiation. To investigate the time kinetics of the differentiation induced by fraction Mc-2, the HL60 cells were treated with Mc-2 at a final concentration of 20 μg/mL and scored for NBT-positive cells from day 1 to day 5 of the treatment. As evident from Figure 1(c), differentiation was observed on day 3, which increased further on day 4 after which no significant change in the percentage of differentiated cells was observed.

3.3. The Differentiation Inducing Component(s) Present in Fraction Mc-2 Are Nonproteinaceous and Heat-Stable. In order to establish the nature of the component(s) responsible for inducing differentiation, fraction Mc-2 was heat-treated at 70°C (Mc-2H) or protease-treated (Mc-2P) for 30 min prior to its use in differentiation. No significant loss in the differentiation inducing ability was observed by these treatments when compared to fraction Mc-2 (Figure 1(d)) suggesting that the differentiation inducing principle(s) are nonproteinaceous in nature.

Further since the principle(s) were found to be nonproteinaceous in nature, different concentrations of acetone extractable component(s) of fraction Mc-2 (designated as Mc-2Ac) were tested for its differentiation inducing potential. The fraction Mc-2Ac induced differentiation in a concentration- and time-dependent manner (Figures 2(a) and 2(b)). The fraction Mc-2Ac showed higher differentiation inducing potential. As evident from the data, fraction Mc-2 showed between 50 and 53% differentiation at 10 and 20 μg/mL, whereas fraction Mc-2Ac was able to bring about 59% differentiation even at 10 μg/mL concentration (cf. Figures 1(a) and 2(a)). Like the parent fraction Mc-2, fraction Mc-2Ac also did not show any cytotoxic effect on HL60 cells even at 5× concentration than that used for differentiation (Figure 2(c)).

3.4. Minimum Time Required for Fraction Mc-2Ac to Trigger Differentiation. To determine the minimum time required for the differentiation to be triggered by fraction Mc-2Ac, the cells were grown in the medium containing fraction Mc-2Ac (20 μg/mL) for different time period followed by their growth in normal medium. Very low percentage of cells was NBT-positive when the cells were grown in the medium containing Mc-2Ac up to 48 h (Figure 2(d)). A significant increase in the NBT-positive cells was recorded when the cells were grown in the medium containing Mc-2Ac for 72 h. Further increase in the time for which the fraction Mc-2Ac was present in the medium resulted in further increase in the NBT-positive cells. The data suggest that fraction Mc-2Ac is required to be present in the medium for at least 72 h to trigger differentiation. The cells show maximum differentiation (~55–59%) when the fraction Mc-2Ac remained present in the medium for 96 h.

3.5. Effect of M. charantia Seed Fractions on HL60 Cells Proliferation. Since many other inducers of differentiation are
known to cause both differentiation and inhibit proliferation [28–30], effect of different fractions of *M. charantia* was also evaluated on proliferation of HL60 cells. As evident from Figure 3, no change in rate of proliferation was noted till day 3 of the treatment, after which a slight decline in the cell count was observed on day 4 and day 5 in the treated samples, when compared to the untreated control.

### 3.6. CD11b Expression in Mc-2Ac-Treated HL60 Cells Confirms Differentiation

Differentiation of HL60 cells treated with Mc-2Ac was further confirmed by analysis of expression of CD11b, a marker of differentiation. An increase in the presence of CD11b positive cells could be detected in the Mc-2Ac-treated HL60 cells from day 3 to day 5, evident by the observed increase in the mean fluorescent intensity, when compared to untreated control (Figures 4(a) and 4(b)). Negligible staining was seen with isotype control and incubation of cells with isotype control Mab did not change cd11b expression (data not shown). The percentage increase in the expression of CD11b in Mc-2Ac-treated cells correlated
well with the number of NBT-positive cells from day 3 to day 5.

3.7. The Acetone Extractable Fraction (Mc-2Ac) Differentiates HL60 Cells into Granulocytes. HL60 cells are predominantly promyelocytic in origin and can be induced to differentiate into granulocytic or monocytic lineages by different inducers. Wright-Giemsa staining of the fractions Mc-2- and Mc-2Ac-treated HL60 cells reveals the presence of HL60 cells of granulocytic lineage. Presence of segmented and banded neutrophils in Mc-2Ac-treated cells is evident from Figure 4(c).

Lineage of differentiation was further confirmed by determination of the specific/nonspecific esterase activity in HL60 cells. The HL60 cells treated with either Mc-2 or Mc-2Ac were found to be positive for specific esterase activity (+2 to +3) and negative (0) for nonspecific esterase activity confirming to the granulocytic differentiation of the HL60 cells by *M. charantia* seed fractions.

3.8. Effect of Fraction Mc-2Ac on *c-myc* Expression in HL60 Cells. Since *c-myc* expression has been reported to be down-regulated in leukemic cells that were induced to differentiate [31–33], *c-myc* transcript levels were measured in HL60 cells treated with fractions Mc-2 and Mc-2Ac on day 4 after treatment. Northern blot analysis performed with total RNA isolated from the control and treated cells revealed a significant decrease in the levels of *c-myc* transcript.
cells. Our results are in agreement with the reports put forth of ethanolic extract of M. charantia and not caused by cell death of immature undi
di
μ
20
positive di
on HL60 cells. These data suggest that the increase in NBT-
ff
inducing di
no decrease in di
3, these inhibitors are fractionated away and that is why
μ
20
their inhibitory e
ff
into HL60 cells. It is clearly demonstrated that fraction Mc-1
compounds that could inhibit di
ff
and its subsequent fractions Mc-2 and Mc-2Ac are able to
ff
in HL60 cells. As Mc-1 is crude extract, a decrease in di
ff
as DFMO or DMSO, that exhibit cytotoxic e
ff
though some di
ff
of HL60 cells on day 1 itself [38]. In the present study, it was
established that presence of Mc-2Ac for a minimum time of
~72 h is required to observe any significant differentiation,
though some differentiation could be observed on day 2
also. Since the fraction Mc-2A did not show any cytotoxic eff et even at 2.5× concentration that induced maximum
differentiation, it is advantageous over other inducers such
d as DFMO or DMSO, that exhibit cytotoxic effect at higher
concentration.

The nature of the differentiation inducing compound(s),
as established by the retention of the differentiation inducing
activity even after heat and protease treatment, is in line
with other studies wherein a large proportion of the inducers
of HL60 differentiation are nonproteinaceous in nature [35,
36]. The extent of differentiation induced with the Mc-2
and Mc-2Ac fractions is comparable with the differentiation
induced by many other plant-derived compounds [42].

M. charantia seed fractions did not exhibit any antiprolif-
erative activity. Till day 3, there was no change in the growth
profile of the treated cells when compared to the untreated
cells. Similar results have been obtained by induction of
differentiation of human K562 cells with hemin [43]. A slight
decline in the cell count in Mc-1, Mc-2, and Mc-2Ac fractions
on day 4 and day 5 of the treatment is due to induction of
differentiation as the differentiated cell population does
not proliferate further. These data suggest that the test
fractions do not possess antiproliferative activity. Although
M. charantia extracts have been reported to have antitumor
and antiproliferative activities ([13–16], for review please see
[10, 44]), most of such activities have been attributed to a
number of proteins identified as lectins—ribosome inacti-
vating proteins such as alpha momorcharin, momordin [7,
15, 45], and MAP30 ([8, 46], for review, please see [10, 44]).
Unlike these, the differentiation inducing fractions did not

Unlike many other plant-derived compounds which in-
duce the HL60 cells towards monocyctic or macrophagic
pathway [35, 36], fractionated M. charantia extracts induced
HL60 cells into granulocytic pathway, evident by the mor-
phological characteristics of granulocytic lineage, presence
of specific esterase activity, and expression of CD11b in the Mc-
2- and Mc-2Ac-treated HL60 cells. Granulocytic differentia-
tion of HL60 cells by fractionated M. charantia seed extract
is comparable to that observed with retinoic acid [25].

Induction of differentiation of HL60 cells by fractionated
M. charantia seed extracts in a time- and concentration-de-
dpendent manner supports the “all or none” response similar
to that of DMSO and sodium butyrate [37] as opposed to
the graded response seen by another inducer of HL60 differ-
entiation such as retinoic acid [25]. It is known that differ-
ent inducers require different lengths of time to trigger dif-
ferentiation in different cell types [38–40]. During this
period, the cells become committed to differentiation and this
has been proposed to be a rate limiting step for the cells to
synthesize cellular constituents above a threshold value [41].
While difluoromethylornithine (DFMO) is reported to trig-
ger differentiation of MEL cells when present in the medium
for only 24 h, vitamin D3 is required to be present for 48 h
in the medium to induce differentiation of MEL cells [40].
On the other hand, vitamin D3 was able to induce differentiation
of HL60 cells on day 1 itself [38]. In the present study, it was
established that presence of Mc-2Ac for a minimum time of

(2.1 Kb) in the Mc-2Ac-treated HL60 cells when compared
to untreated control (Figure 5). These data suggest that the
differentiation induction by M. charantia seed fraction may,
in part, involve c-myc pathway.

4. Discussion

In the present study, we for the first time demonstrate the
differentiation induction potential of the M. charantia seeds
in HL60 cells. It is clearly demonstrated that fraction Mc-1
and its subsequent fractions Mc-2 and Mc-2Ac are able to
differentiate HL60 cells. As Mc-1 is crude extract, a decrease
in the differentiated cells in Mc-1-treated cells at higher
concentration (i.e., 20 μg/mL) in comparison with that observed
with 10 μg/mL could possibly be due to the presence of some
compounds that could inhibit differentiation and which gain
their inhibitory effect when concentration is increased to
20 μg/mL. Upon further fractionation into Mc-2 and Mc-
3, these inhibitors are fractionated away and that is why
no decrease in differentiation is seen in fractions Mc-2 at
20 μg/mL. The test fractions of M. charantia capable of
inducing differentiation did not exhibit any cytotoxic effect
on HL60 cells. These data suggest that the increase in NBT-
positive differentiated cells upon treatment is indeed due to
differentiation brought about by the M. charantia fractions
and not caused by cell death of immature undifferentiated
cells. Our results are in agreement with the reports put forth
by Sharma et al., who also did not observe any cytotoxic effect
of ethanolic extract of M. charantia on a number of cancer
cells [34].

Figure 3: The effect of different fractions of M. charantia seed
extract on the growth of HL60 cells. Cells were treated with differ-
ent concentrations of fractions Mc-1, Mc-2, Mc-3 and Mc-2Ac
(each at 20 μg/mL concentration) for 5 days. Viable cell count was
determined at different posttreatment intervals. The data represent
means ± SD of three parallel experiments.
exhibit any antiproliferative activity and the differentiation inducing principle(s) was found to be nonproteinaceous in nature, suggesting that the differentiation inducing factors of M. charantia are different from its antitumor factors.

Since HL60 cells are induced to differentiate by retinoic acid, it was imperative to rule out the possibility that the differentiation by M. charantia extract is not due to retinoic acid present in the extracts, if any. For this purpose, differentiation inducing potential of the fraction Mc-1 was assessed in K562 cells, prototype human myeloid leukemia cell type that is resistant to retinoic acid induced differentiation [28, 47] by morphological examination as described earlier [48]. While treatment with positive inducer sodium butyrate resulted in upto 85–90% cells to be differentiated, fraction Mc-1 resulted in differentiation of ∼40–45% cells (Ramani Soundararajan, Madhu Geeta, and Aparna Dixit,
unpublished data). Vitamin A levels have been reported to be undetectable in methanolic extracts of *M. charantia* [49]. In the present study, seed extraction was performed with acid ethanol, and therefore, it was unlikely to have retinoic acid. Analysis of the test fractions Mc-1, Mc-2, Mc-3, and Mc-2A for vitamin A content by LC-MS-MS confirmed that these fractions did not contain vitamin A (data not shown). Thus, the ability of *M. charantia* seed extract to induce differentiation of vitamin A resistant K562 cells and absence of vitamin A in the test fractions of *M. charantia* suggest that the differentiation brought about by these fractions in the present study is not brought about by retinoic acid.

The transcription factor c-Myc plays a role in the control of cell proliferation and differentiation [50]. A significant decrease in the c-myc expression in the Mc-2- and Mc-2Ac-treated cells is in line with previous reports wherein a modulation in c-myc expression in HL60 cells induced to differentiate has been established [31, 32]. Murine erythroleukemic (MEL) cells induced to differentiate by DMSO also showed a biphasic change in the c-myc levels suggesting that the changes in c-myc may be important for irreversible commitment of MEL cells towards terminal erythroid lineage [33]. The reduced expression of c-myc can be related to the loss of proliferative potential of the differentiated cells [32]. A slight decrease in c-myc transcript in the Mc-2Ac-treated cells relates well with the decrease in number of cells from day 3 onwards, relating to the loss of proliferating potential of the differentiated cells as c-Myc has been shown to be functionally involved in DNA synthesis [51]. Thus, the present study for the first time demonstrates differentiation inducing activity of the fractionated *M. charantia* seed extracts which can be further assessed as inducer of differentiation for the treatment of APL, either alone or in combination with the suboptimal concentrations of other known inducers of differentiation. Studies are in progress to understand the mechanism by which the compounds present in fraction Mc-2Ac are inducing differentiation.

**Abbreviations**

DMSO: Dimethyl sulfoxide
DFMO: Difluoromethylornithine
PMSF: Phenylmethylsulfonyl fluoride
NBT: Nitroblue tetrazolium.

**Authors’ Contribution**

R. Soundararajan and P. Prabha have contributed equally to this work.

**Acknowledgments**

The University Grants Commission, New Delhi, is acknowledged for providing financial support. Mr. Amaresh Kumar Singh is acknowledged for technical assistance.

**References**


**Evidence-Based Complementary and Alternative Medicine**

**Figure 5:** Northern blot analysis of c-myc expression in the control (lanes 1 and 2), Mc-2- (lane 3), and Mc-2A- (lane 4) treated HL60 cells. Top panel shows the 2.1 Kb c-myc transcripts. An identical gel stained with ethidium bromide is included as loading control (bottom panel).
Evidence-Based Complementary and Alternative Medicine


Submit your manuscripts at http://www.hindawi.com